<i>KRAS</i> Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

20081,450 citationsJournal Articlebronze Open Access

Authors

Astrid Lièvre · Université de Versailles Saint-Quentin-en-Yvelines

Jean‐Baptiste Bachet · Université de Versailles Saint-Quentin-en-Yvelines

Valérie Boige · Université de Versailles Saint-Quentin-en-Yvelines

Anne Cayre · Université de Versailles Saint-Quentin-en-Yvelines

Delphine Le Corre · Université de Versailles Saint-Quentin-en-Yvelines

Emmanuel Buc · Université de Versailles Saint-Quentin-en-Yvelines

Abstract

These results confirm the high prognostic value of KRAS mutations on response to cetuximab and survival in metastatic CRC patients treated with cetuximab.

Topics & Keywords

Colorectal Cancer Treatments and Studies Genetic factors in colorectal cancer Colorectal and Anal Carcinomas

UN Sustainable Development Goals

Reduced inequalities

Publication Details

Published in: Journal of Clinical Oncology

Volume 26, Issue 3, pp. 374-379

DOI: 10.1200/jco.2007.12.5906

Field-Weighted Citation Impact: 92.34